Nuvalent director’s awards cashed out in GSK deal
SEC Form 4 FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP…
Nuvalent director tenders shares in $124 GSK buyout
SEC Form 4 FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP…
GSK Completes Nuvalent Tender Offer at $124 Per Share | NUVL SEC Filing
This Amendment No. 4 (this “Amendment”) amends and supplements the Tender Offer Statement on Schedule TO (together with any…
Nuvalent takeover: HSR waiting period cleared, $124 per share offer | GSK SEC Filing
This Amendment No. 3 (this “Amendment”) amends and supplements the Tender Offer Statement on Schedule TO (together with any…
GSK offers $124 per share to acquire Nuvalent | NUVL SEC Filing
This Amendment No. 2 (this “Amendment”) amends and supplements the Tender Offer Statement on Schedule TO (together with any…
GSK offers $124.00 per share for Nuvalent | NUVL SEC Filing
This Amendment No. 1 (this “Amendment”) amends and supplements the Tender Offer Statement on Schedule TO (together with any…
GSK and NUVL Stocks Put Biotech M&A and Patent Cliff Deals in Focus for Investors
The sudden $10.6 billion acquisition of Nuvalent NASDAQ: NUVL by GSK NYSE: GSK violently shatters a lingering mergers…
Nuvalent Soars 39% as GSK Agrees $10.6 Billion Takeover; FDA Catalysts and Oncology Pipeline Drive Bullish Momentum
Nuvalent (NASDAQ: NUVL) surged nearly 39.3% to $123.25 on June 9 after GSK agreed to acquire the precision…